Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies
Heiko Kroth, Felix Oden, Jérôme Molette, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2019) Vol. 46, Iss. 10, pp. 2178-2189
Open Access | Times Cited: 190

Showing 1-25 of 190 citing articles:

High-Contrast In Vivo Imaging of Tau Pathologies in Alzheimer’s and Non-Alzheimer’s Disease Tauopathies
Kenji Tagai, Maiko Ono, Manabu Kubota, et al.
Neuron (2020) Vol. 109, Iss. 1, pp. 42-58.e8
Open Access | Times Cited: 208
Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy
Matthias Brendel, Henryk Barthel, Thilo van Eimeren, et al.
JAMA Neurology (2020) Vol. 77, Iss. 11, pp. 1408-1408
Open Access | Times Cited: 202
Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research
Christina M. Moloney, Val J. Lowe, Melissa E. Murray
Alzheimer s & Dementia (2021) Vol. 17, Iss. 9, pp. 1554-1574
Open Access | Times Cited: 197
Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade
George Crișan, Nastasia Sanda Moldovean-Cioroianu, Diana-Gabriela Timaru, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 5023-5023
Open Access | Times Cited: 184
Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases
Urmi Sengupta, Rakez Kayed
Progress in Neurobiology (2022) Vol. 214, pp. 102270-102270
Open Access | Times Cited: 166
Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer's disease and mild cognitive impairment
Avinash Chandra, Polytimi‐Eleni Valkimadi, Gennaro Pagano, et al.
Human Brain Mapping (2019) Vol. 40, Iss. 18, pp. 5424-5442
Open Access | Times Cited: 157
Tau PET imaging with 18F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study
André Mueller, Santiago Bullich, Olivier Barret, et al.
Journal of Nuclear Medicine (2019) Vol. 61, Iss. 6, pp. 911-919
Open Access | Times Cited: 157
Tau deposition patterns are associated with functional connectivity in primary tauopathies
Nicolai Franzmeier, Matthias Brendel, Leonie Beyer, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 73
Targeted Dephosphorylation of Tau by Phosphorylation Targeting Chimeras (PhosTACs) as a Therapeutic Modality
Zhenyi Hu, Po‐Han Chen, Wenxue Li, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 7, pp. 4045-4055
Closed Access | Times Cited: 52
Head-to-head comparison of [18F]-Flortaucipir, [18F]-MK-6240 and [18F]-PI-2620 postmortem binding across the spectrum of neurodegenerative diseases
Cinthya Agüero, Maëva Dhaynaut, Ana C. Amaral, et al.
Acta Neuropathologica (2024) Vol. 147, Iss. 1
Open Access | Times Cited: 23
Current Progress and Future Directions in Non-Alzheimer’s Disease Tau PET Tracers
Hendris Wongso, Ryuichi Harada, Shozo Furumoto
ACS Chemical Neuroscience (2025) Vol. 16, Iss. 2, pp. 111-127
Closed Access | Times Cited: 3
Targeting Tau Protein with Proximity Inducing Modulators: A New Frontier to Combat Tauopathies
Elisa Uliassi, María Laura Bolognesi, Andrea Milelli
ACS Pharmacology & Translational Science (2025) Vol. 8, Iss. 3, pp. 654-672
Closed Access | Times Cited: 2
Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development
Stuart P. McCluskey, Christophe Plisson, Eugenii A. Rabiner, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2019) Vol. 47, Iss. 2, pp. 451-489
Open Access | Times Cited: 105
PET Radiopharmaceuticals for Alzheimer’s Disease and Parkinson’s Disease Diagnosis, the Current and Future Landscape
Bright Chukwunwike Uzuegbunam, Damiano Librizzi, Behrooz H. Yousefi
Molecules (2020) Vol. 25, Iss. 4, pp. 977-977
Open Access | Times Cited: 96
Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies
María Stamelou, Gesine Respondek, Nikolaos Giagkou, et al.
Nature Reviews Neurology (2021) Vol. 17, Iss. 10, pp. 601-620
Closed Access | Times Cited: 94
Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease
Caitlin V. M. L. Jie, Valérie Treyer, Roger Schibli, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 2, pp. 110-110
Open Access | Times Cited: 92
Cortical [18F]PI‐2620 Binding Differentiates Corticobasal Syndrome Subtypes
Carla Palleis, Matthias Brendel, Anika Finze, et al.
Movement Disorders (2021) Vol. 36, Iss. 9, pp. 2104-2115
Open Access | Times Cited: 68
Neuropathology and emerging biomarkers in corticobasal syndrome
Shunsuke Koga, Keith A. Josephs, Ikuko Aiba, et al.
Journal of Neurology Neurosurgery & Psychiatry (2022) Vol. 93, Iss. 9, pp. 919-929
Open Access | Times Cited: 65
Evaluation of [18F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies
Toshiki Tezuka, Keisuke Takahata, Morinobu Seki, et al.
Brain Communications (2021) Vol. 3, Iss. 4
Open Access | Times Cited: 63
Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study
Aisling M. Chaney, Francisco R. López-Picón, Sophie Sérrière, et al.
Theranostics (2021) Vol. 11, Iss. 14, pp. 6644-6667
Open Access | Times Cited: 61
Current directions in tau research: Highlights from Tau 2020
Claire E. Sexton, Heather M. Snyder, Dirk Beher, et al.
Alzheimer s & Dementia (2021) Vol. 18, Iss. 5, pp. 988-1007
Open Access | Times Cited: 61
Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer’s disease, corticobasal degeneration and progressive supranuclear palsy brains
Mona‐Lisa Malarte, Per‐Göran Gillberg, Amit Kumar, et al.
Molecular Psychiatry (2022) Vol. 28, Iss. 3, pp. 1272-1283
Open Access | Times Cited: 42
Overview of tau PET molecular imaging
Gabriel Cassinelli Petersen, Michelle Roytman, Gloria C. Chiang, et al.
Current Opinion in Neurology (2022) Vol. 35, Iss. 2, pp. 230-239
Open Access | Times Cited: 41
Clinical Spectrum of Tauopathies
Nahid Olfati, Ali Shoeibi, Irene Litvan
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 41
CenTauR: Toward a universal scale and masks for standardizing tau imaging studies
Victor L. Villemagne, Antoine Leuzy, Sandra Sanabria Bohórquez, et al.
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring (2023) Vol. 15, Iss. 3
Open Access | Times Cited: 28
Page 1 - Next Page

Scroll to top